Abstract
Most cancer cells contain high levels of reactive oxygen species (ROS), which result in higher expression levels of the glutathione and thioredoxin reductase systems. These antioxidant systems convert ROS to nonharmful compounds and they also reduce disulfide bonds in oxidized proteins. They also control the glutathionylation and nitrosylation of proteins, which alters the activity of the proteins. Through these functions the upregulated antioxidant systems act on transcription factors and on signaling pathways, which result in the promotion of cancer cell growth and the prevention of cell apoptosis. High levels of certain members of the glutathione and thioredoxin systems in specific cancers correlate with poor patient prognosis and with drug resistance. Therefore, these antioxidants represent a potential new target for chemotherapy treatments, especially the thioredoxin reductase (TrxR) protein, which can be targeted through its selenocysteine residue. Inhibition of TrxR leads to increased ROS levels in cancer cells to a lethal level, consequently leading to activation of cell death mechanisms. However, ROS levels remain at nonlethal levels in normal cells, thus enabling specific targeting of cancer cells. The design and availability of inhibitors for the specific upregulated antioxidant proteins in each type of cancer may also overcome drug resistance by resensitizing cancers to existing chemotherapy treatments.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anestal K, Prast-Nielsen S, Cenas N, Arner ES (2008) Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells. PLoS One 3:e1846. https://doi.org/10.1371/journal.pone.0001846
Arevalo JA, Vazquez-Medina JP (2018) The role of Peroxiredoxin 6 in cell signaling. Antioxidants 7(12):172. https://doi.org/10.3390/antiox7120172
Arner ES (2020) Perspectives of TrxR1-based cancer therapies. In: Sies H (ed) Oxidative stress: eustress and distress. Elsevier, Amsterdam, The Netherlands, pp 639–667
Baker AF, Adab KN, Raghunand N, Chow H, Stratton SP, Squire SW, Boice M, Pestano LA, Kirkpatrick DL, Dragovich T (2013) A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers. Investig New Drugs 31:631–641. https://doi.org/10.1007/s10637-012-9846-2
Bansal A, Simon MC (2018) Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol 217:2291–2298. https://doi.org/10.1083/jcb.201804161
Benhar M (2020) Oxidants, antioxidants and thiol redox switches in the control of regulated cell death pathways. Antioxidants 9:309. https://doi.org/10.3390/antiox9040309
Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, Powis G (1996) Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 16:3459–3466
Bhatia M, McGrath KL, Di Trapani G, Charoentong P, Shah F, King MM, Clarke FM, Tonissen KF (2016) The thioredoxin system in breast cancer cell invasion and migration. Redox Biol 8:68–78. https://doi.org/10.1016/j.redox.2015.12.004
Boveris A, Chance B (1973) The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 134:707–716
Brigelius-Flohe R, Maiorino M (2013) Glutathione peroxidases. Biochim Biophys Acta 1830:3289–3303. https://doi.org/10.1016/j.bbagen.2012.11.020
Casagrande S, Bonetto V, Fratelli M, Gianazza E, Eberini I, Massignan T, Salmona M, Chang G, Holmgren A, Ghezzi P (2002) Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci U S A 99:9745–9749. https://doi.org/10.1073/pnas.152168599
Chae HZ, Oubrahim H, Park JW, Rhee SG, Chock PB (2012) Protein glutathionylation in the regulation of peroxiredoxins: a family of thiol-specific peroxidases that function as antioxidants, molecular chaperones, and signal modulators. Antioxid Redox Signal 16:506–523. https://doi.org/10.1089/ars.2011.4260
Chandra J (2009) Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies. Antioxid Redox Signal 11:1123–1137. https://doi.org/10.1089/ARS.2008.2302
Chang T-S, Jeong W, Woo HA, Lee SM, Park S, Rhee SG (2004) Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J Biol Chem 279:50994–51001
Chen HH, Kuo MT (2010) Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010:1–7. https://doi.org/10.1155/2010/430939
Cheng WH, Ho YS, Valentine BA, Ross DA, Combs GF Jr, Lei XG (1998) Cellular glutathione peroxidase is the mediator of body selenium to protect against paraquat lethality in transgenic mice. J Nutr 128:1070–1076. https://doi.org/10.1093/jn/128.7.1070
Cheng Q, Sandalova T, Lindqvist Y, Arnér ES (2008) Crystal structure and catalysis of the selenoprotein thioredoxin reductase 1. J Biol Chem 284:3998–4008
Cheng P, Liu H, Li Y, Pi P, Jiang Y, Zang S, Li X, Fu A, Ren X, Xu J, Holmgren A, Lu J (2020) Inhibition of thioredoxin reductase 1 correlates with platinum-based chemotherapeutic induced tissue injury. Biochem Pharmacol:113873. https://doi.org/10.1016/j.bcp.2020.113873
Cooper AJ, Pinto JT, Callery PS (2011) Reversible and irreversible protein glutathionylation: biological and clinical aspects. Expert Opin Drug Metab Toxicol 7:891–910. https://doi.org/10.1517/17425255.2011.577738
Dalton TP, Dieter MZ, Yang Y, Shertzer HG, Nebert DW (2000) Knockout of the mouse glutamate cysteine ligase catalytic subunit (Gclc) gene: embryonic lethal when homozygous, and proposed model for moderate glutathione deficiency when heterozygous. Biochem Biophys Res Commun 279:324–329
Desideri E, Ciccarone F, Ciriolo MR (2019) Targeting glutathione metabolism: partner in crime in anticancer therapy. Nutrients 11(8):1926. https://doi.org/10.3390/nu11081926
Farina AR, Cappabianca L, DeSantis G, Di Ianni N, Ruggeri P, Ragone M, Merolle S, Tonissen KF, Gulino A, Mackay AR (2011) Thioredoxin stimulates MMP-9 expression, de-regulates the MMP-9/TIMP-1 equilibrium and promotes MMP-9 dependent invasion in human MDA-MB-231 breast cancer cells. FEBS Lett 585:3328–3336. https://doi.org/10.1016/j.febslet.2011.09.023
Go YM, Roede JR, Walker DI, Duong DM, Seyfried NT, Orr M, Liang Y, Pennell KD, Jones DP (2013) Selective targeting of the cysteine proteome by thioredoxin and glutathione redox systems. Mol Cell Proteomics 12:3285–3296. https://doi.org/10.1074/mcp.M113.030437
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Hawk MA, McCallister C, Schafer ZT (2016) Antioxidant activity during tumor progression: a necessity for the survival of Cancer cells? Cancers 8(10):92. https://doi.org/10.3390/cancers8100092
Hayes JD, Dinkova-Kostova AT (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39:199–218. https://doi.org/10.1016/j.tibs.2014.02.002
Hirota K, Matsui M, Iwata S, Nishiyama A, Mori K, Yodoi J (1997) AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A 94:3633–3638
Holmgren A (1985) Thioredoxin. Annu Rev Biochem 54:237–271
Kim SJ, Miyoshi Y, Taguchi T, Tamaki Y, Nakamura H, Yodoi J, Kato K, Noguchi S (2005) High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 11:8425–8430. https://doi.org/10.1158/1078-0432.CCR-05-0449
Knoops B, Goemaere J, Van der Eecken V, Declercq JP (2011) Peroxiredoxin 5: structure, mechanism, and function of the mammalian atypical 2-Cys peroxiredoxin. Antioxid Redox Signal 15:817–829. https://doi.org/10.1089/ars.2010.3584
Kumari S, Badana AK, G MM, G S, Malla R (2018) Reactive oxygen species: a key constituent in Cancer survival. Biomark Insights 13:1177271918755391. https://doi.org/10.1177/1177271918755391
Leone A, Roca MS, Ciardiello C, Costantini S, Budillon A (2017) Oxidative stress gene expression profile correlates with Cancer patient poor prognosis: identification of crucial pathways might select novel therapeutic approaches. Oxidative Med Cell Longev 2017:2597581. https://doi.org/10.1155/2017/2597581
Lillig CH, Berndt C, Holmgren A (2008) Glutaredoxin systems. Biochim Biophys Acta 1780:1304–1317. https://doi.org/10.1016/j.bbagen.2008.06.003
Lincoln DT, Ali EE, Tonissen KF, Clarke FM (2003) The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 23:2425–2433
Lu J, Holmgren A (2014) The thioredoxin antioxidant system. Free Radic Biol Med 66:75–87
Matsui M, Oshima M, Oshima H, Takaku K, Maruyama T, Yodoi J, Taketo MM (1996) Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol 178:179–185
Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711–760
Mitchell DA, Marletta MA (2005) Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine. Nat Chem Biol 1:154
Nishiyama A, Masutani H, Nakamura H, Nishinaka Y, Yodoi J (2001) Redox regulation by thioredoxin and thioredoxin-binding proteins. IUBMB Life 52:29–33
Noguera-Mazon V, Lemoine J, Walker O, Rouhier N, Salvador A, Jacquot JP, Lancelin JM, Krimm I (2006) Glutathionylation induces the dissociation of 1-Cys D-peroxiredoxin non-covalent homodimer. J Biol Chem 281:31736–31742. https://doi.org/10.1074/jbc.M602188200
Pan S, Berk BC (2007) Glutathiolation regulates tumor necrosis factor-alpha-induced caspase-3 cleavage and apoptosis: key role for glutaredoxin in the death pathway. Circ Res 100:213–219. https://doi.org/10.1161/01.RES.0000256089.30318.20
Qin J, Clore GM, Kennedy WP, Huth JR, Gronenborn AM (1995) Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NFκB. Structure 3:289–297
Raninga PV, Di Trapani G, Vuckovic S, Bhatia M, Tonissen KF (2015) Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma. Oncotarget 6:15410
Raninga PV, Di Trapani G, Vuckovic S, Tonissen KF (2016) TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-small ka, Cyrillicbeta inhibition. Cell Cycle 15:559–572. https://doi.org/10.1080/15384101.2015.1136038
Reddie KG, Carroll KS (2008) Expanding the functional diversity of proteins through cysteine oxidation. Curr Opin Chem Biol 12:746–754
Rhee SG, Kil IS (2017) Multiple functions and regulation of mammalian Peroxiredoxins. Annu Rev Biochem 86:749–775. https://doi.org/10.1146/annurev-biochem-060815-014431
Roder C, Thomson MJ (2015) Auranofin: repurposing an old drug for a golden new age. Drugs R D 15:13–20. https://doi.org/10.1007/s40268-015-0083-y
Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H (1998) Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17:2596–2606
Schachtele SJ, Hu S, Lokensgard JR (2012) Modulation of experimental herpes encephalitis-associated neurotoxicity through sulforaphane treatment. PLoS One 7:e36216. https://doi.org/10.1371/journal.pone.0036216
Schieber M, Chandel NS (2014) ROS function in redox signaling and oxidative stress. Curr Biol 24:R453–R462
Stafford WC, Peng X, Olofsson MH, Zhang X, Luci DK, Lu L, Cheng Q, Tresaugues L, Dexheimer TS, Coussens NP, Augsten M, Ahlzen HM, Orwar O, Ostman A, Stone-Elander S, Maloney DJ, Jadhav A, Simeonov A, Linder S, Arner ESJ (2018) Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci Transl Med 10. https://doi.org/10.1126/scitranslmed.aaf7444
Sze JH, Raninga PV, Nakamura K, Casey M, Khanna KK, Berners-Price SJ, Di Trapani G, Tonissen KF (2020) Anticancer activity of a gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma. Redox Biol 28:101310. https://doi.org/10.1016/j.redox.2019.101310
Ueno M, Masutani H, Arai RJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka Y, Yodoi J, Nikaido T (1999) Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 274:35809–35815. https://doi.org/10.1074/jbc.274.50.35809
van Bergen LA, Roos G, De Proft F (2014) From thiol to sulfonic acid: modeling the oxidation pathway of protein thiols by hydrogen peroxide. J Phys Chem A 118:6078–6084
Wang J, Yang H, Li W, Xu H, Yang X, Gan L (2015) Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug resistance in ovarian cancer cells. Biochim Biophys Acta 1852:395–405. https://doi.org/10.1016/j.bbadis.2014.12.002
Welsh SJ, Bellamy WT, Briehl MM, Powis G (2002) The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62:5089–5095
Xiong Y, Uys JD, Tew KD, Townsend DM (2011) S-glutathionylation: from molecular mechanisms to health outcomes. Antioxid Redox Signal 15:233–270. https://doi.org/10.1089/ars.2010.3540
Zeligs KP, Neuman MK, Annunziata CM (2016) Molecular pathways: the balance between Cancer and the immune system challenges the therapeutic specificity of targeting nuclear factor-kappaB signaling for Cancer treatment. Clin Cancer Res 22:4302–4308. https://doi.org/10.1158/1078-0432.CCR-15-1374
Zhang ZZ, Lee EE, Sudderth J, Yue Y, Zia A, Glass D, Deberardinis RJ, Wang RC (2016) Glutathione depletion, pentose phosphate pathway activation, and hemolysis in erythrocytes protecting Cancer cells from vitamin C-induced oxidative stress. J Biol Chem 291:22861–22867. https://doi.org/10.1074/jbc.C116.748848
Zhang X, Selvaraju K, Saei AA, D’Arcy P, Zubarev RA, Arner ES, Linder S (2019) Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug. Biochimie 162:46–54. https://doi.org/10.1016/j.biochi.2019.03.015
Zhong L, Arnér ES, Holmgren A (2000) Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc Natl Acad Sci U S A 97:5854–5859
Zhu H, Tao X, Zhou L, Sheng B, Zhu X, Zhu X (2019) Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT. BMC Cancer 19:865. https://doi.org/10.1186/s12885-019-6046-x
Zorov DB, Juhaszova M, Sollott SJ (2014) Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 94:909–950
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Yu, Y., Di Trapani, G., Tonissen, K.F. (2022). Thioredoxin and Glutathione Systems. In: Chakraborti, S., Ray, B.K., Roychoudhury, S. (eds) Handbook of Oxidative Stress in Cancer: Mechanistic Aspects. Springer, Singapore. https://doi.org/10.1007/978-981-15-9411-3_143
Download citation
DOI: https://doi.org/10.1007/978-981-15-9411-3_143
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-9410-6
Online ISBN: 978-981-15-9411-3
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences